BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...
Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.
HSE bosses have advised people to apply for a little-known health scheme that thousands are eligible for. The Long-Term ...
Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with two ongoing clinical-stage programs – MZE829 for ...
Get the latest lifestyle updates on Times of India, along with EID Wishes, Messages and quotes !
StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating ...
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...
Korea Investment CORP grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 362.5% ...
2d
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...
Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.
Learn more about whether Alvotech or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback